MedShr grows to a million members in less than 5 years
11 February, 2020
MedShr, the professional social network for doctors, has grown rapidly to over one million members in 190 countries
Developed by doctors and launched in 2015, MedShr is a HIPAA, GMC and GDPR-compliant app designed to empower medical professionals to safely discuss clinical cases using their own smartphone.
MedShr provides a unique digital channel for medical professionals to share their knowledge and skills, discuss complex and challenging cases, and learn from one another. Screening and diagnosis of coronavirus is currently among the trending topics, discussed at a global level between specialists and generalists alike with a unique perspective from a global health point of view.
Founder Dr Asif Qasim said: “MedShr is growing rapidly and has become a part of everyday clinical practice for many doctors through international speciality networks as well as local multi-disciplinary groups. I am incredibly proud of our members and the MedShr team for the work they have done to improve healthcare for patients around the world. We are looking forward to MedShr’s continued growth in the US and Europe, and will be providing members with new features and services during 2020.”
MedShr has won multiple awards including Facebook’s Social Good App of the Year 2016, United Nations World Summit Award 2017 and ES SME Award in 2018, was a 2019 TechCrunch DT50 Award for Social Impact finalist, and was recently MedShr was named one of the UK’s top 70 high growth technology companies. MedShr has also been shortlisted for the London Business Awards 2020.
The platform works in partnership with healthcare providers and hundreds of national and specialist medical societies, as well as the NHS, Health Education England and several Royal Colleges.
MedShr is now the world’s leading case discussion app and is now building additional partnerships with US national and specialist medical societies.
Information for editors
2019 year was an exciting year for MedShr – they earned a place among finalists for the TechCrunch Digital Top 50 Award, were selected to take part in the prestigious Vienna Health Hub, and were named on the list of the UK’s Top 70 Fast Growing Tech companies.
MedShr – the HIPAA, GMC and GDPR compliant App for Doctors – is the world’s leading case discussion platform, enabling clinicians to securely share and discuss clinical images and cases within a global professional network. MedShr is growing rapidly with over one million members in 190 countries, working in partnership with hundreds of national and specialist medical societies across all clinical specialities.
MedShr provides a unique digital channel for the pharmaceutical and device industry to engage with physicians and provide independent medical education at scale to the relevant doctor and healthcare professional audiences. They are working with global pharmaceutical and medical device clients to reach and engage clinicians around specific educational objectives in a disease area. To maintain the integrity of clinical case discussions and to ensure information governance requirements are met, industry employees are not allowed access to MedShr cases, members or discussions. Data from the MedShr platform can also provide deep healthcare insights and market information to the industry.
About Dr Asif Qasim
Asif is the Founder and CEO of MedShr, the world’s leading clinical case discussion network with over one million members in 190 countries. An angel Investor in media, publishing, film and technology, Asif mentors startup Founders and clinical entrepreneurs, and is a board advisor to a number of early-stage companies.
Following his PhD in Cardiovascular Medicine at Cambridge, he completed his Interventional Cardiology training with a prestigious fellowship in Milan. Described by colleagues as an “inspirational leader” he has held NHS Clinical Director roles, improving the quality of care for patients in acute and community services. Asif is currently a Consultant Interventional Cardiologist with NHS and private practice in London, remains active in research and is a faculty member for major international cardiology congresses.